Recombinant IL13 (Abrezekimab Biosimilar) anticorps
Aperçu rapide pour Recombinant IL13 (Abrezekimab Biosimilar) anticorps (ABIN7676010)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Application
-
-
Expression System
- CHO Cells
-
Fonction
- Anti-IL-13 Reference Antibody (abrezekimab)
-
Séquence
- QVTLKESGPV LVKPTETLTL TCTVSGFSLT NYHVQWIRQP PGKALEWLGV MWSDGDTSFN SVLKSRLTIS RDTSKSQVVL TMTNMDPVDT ATYYCARDGT IAAMDYFDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSC,DIQMTQSPSS LSASVGDRVT ITCLASEDIS NYLAWYQQKP GKAPKLLIYH TSRLQDGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GYRFPLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
-
Attributs du produit
- Anti-IL-13 Reference Antibody (abrezekimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Pureté
- >95 %
-
Isotype
- IgG1
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Commentaires
-
Therapeutic Agents by Target and Mechanism: IL-13 inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Stock
- 4 °C,-80 °C
-
Stockage commentaire
- +4°C,-80°C
-
-
- IL13 (Abrezekimab Biosimilar)
-
Autre désignation
- IL-13 (Abrezekimab Biosimilar)
-
Classe de substances
- Biosimilar
-
Poids moléculaire
- 145.5 kDa
-
UniProt
- P35225
Antigène
-